PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104566
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104566
Bilirubin Testing market size was valued at US$ 2,230.8 Million in 2025, expanding at a CAGR of 4.2% from 2026 to 2033.
A bilirubin laboratory test is a clinical chemistry test that helps measure levels of the orange-yellow bilirubin substance in the blood and provides a vital marker for jaundice, poor functioning of the liver, and the rate of breakdown of the red blood cells. The bilirubin test relies on the use of a venous blood sample mixed with the diazo reagent to conduct colorimetric analysis of the bilirubin. This is because the bilirubin is separated into conjugated bilirubin and unconjugated bilirubin, and their concentrations are measured using an analyzer. Thus, bilirubin testing enables accurate diagnosis, effective disease monitoring, and timely clinical decision-making.
Bilirubin Testing Market- Market Dynamics
Growing demand for early diagnosis to propel market demand
Growing demand for early diagnosis is driving the Bilirubin Testing market because awareness about neonatal jaundice is on the rise, incidences of liver diseases are high, and there is an increasing need for fast and reliable diagnostic tests in the hospitals and clinics. For instance, in 2026, according to the OECD, there is a need to have access to the cancer diagnosis at the earliest in order to satisfy the requirement for the early detection of cancer. The rate of early diagnosis of breast cancer was 56% and that of cervical cancer was 62%, while that of colorectal cancer was 22%. Clearly, there is a need for more effective screening procedures, faster and accurate diagnostic testing, and early treatment to ensure that the patients survive their diseases. Therefore, there will be an increased focus on early disease detection and hence drive the growth of bilirubin testing globally.
The Global Bilirubin Testing market is segmented on the basis of Product, Technology, Application, Patient, End Use, and Region.
Among the given products, bilirubin reagent kits and assay consumables account for a prominent market share in the products that are listed, as these products are frequently utilized for the tests that are conducted regularly along with being vital for the determination of the bilirubin level in the test. In July 2025, Nova Biomedical launched its latest version of the BR2 Bilirubin Test Kit that has pre-packed assay consumables that aid in quick testing of total and direct bilirubin levels. Thus, use of bilirubin reagent kits is still widely supported.
Bilirubin Testing Market- Geographical Insights
North America holds notable share in the Bilirubin Testing market because of the presence of highly developed health care infrastructure, early screening of jaundice in newborns, and an increased number of cases of liver diseases. For instance, in 2026, according to the U.S. Centers for Disease Control and Prevention (CDC), chronic liver disease is an important health problem in the country; there are about 4.5 million US adults with liver disease, with 1.8% of the US population aged 18 years and above suffering from liver disease. There are 52,274 people in America dying due to chronic liver disease and cirrhosis, with a death rate of 15.4 deaths per 100,000 people; that makes chronic liver disease and cirrhosis the ninth leading cause of mortality in the United States. In this regard, the growing incidences of liver diseases have driven the adoption of advanced bilirubin testing kits.
France's industry of bilirubin testing is growing due to the modernization of hospitals' laboratories, the use of automated systems for clinical chemistry, and various healthcare programs related to prevention and treatment of diseases. For instance, in 2025, according to MedTech Europe, France will have one of the largest IVD markets in Europe and will be worth about (USD 2,400 million). The report indicates that the trend of modernization of hospital laboratories is caused by the extensive use of automated diagnostic systems, as well as using molecular diagnostics and digitalization of the workflow in clinical laboratories in order to accelerate the process of diagnosing in the health care system of the country. This investment is to speed up adoption of the latest solutions in bilirubin testing throughout France.
The Bilirubin Testing market comprises major players such as Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, Inc. These companies have increased their market share through innovations in diagnostics and automation in laboratories and testing systems, as well as through their growing geographical presence and portfolio. In November 2025, Abbott Laboratories acquired Exact Sciences in order to integrate the diagnostics of Abbott, which include laboratory testing and precision diagnostics. The acquisition will help Abbott to integrate Exact Sciences in the laboratory test segment, which will add advanced clinical diagnostic capabilities to Abbott's capabilities. These strategic initiatives enhance diagnostic capabilities, accelerate innovation, and strengthen competitive positioning in the bilirubin testing market.
In March 2026, Siemens Healthineers AG (Frankfurt, Germany) launched the Atellica IM pTau217 and BDTau immunoassays as tests for research purposes. These are part of Siemens' Atellica IM portfolio that is now being expanded with next-generation biomarker assays, improving their integrated solution for clinical chemistry and immunoassay testing capabilities.
In January 2025, Thermo Fisher Scientific Inc. acquired the Purification & Filtration Division of Solventum under an acquisition that was valued at about $4.1 billion. The acquisition is expected to expand Thermo Fisher's product range which includes the analytical and clinical laboratory products for conducting diagnostics tests.